December 15, 2017

Madhav Namjoshi Celebrates Over 20 Years of Professional Excellence in Research

    NEW YORK, NY, December 15, 2017 /24-7PressRelease/ -- Madhav Namjoshi has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

For over 20 years, Madhav Namjoshi has excelled in the field of healthcare, research, health economics, and marketing. Madhav earned a Bachelors degree in Pharmacy in 1992, a Masters in Administrative Pharmacy in 1995, a Doctoral degree in Pharmaceutical Socio-Economics in 1998, and an MBA in Marketing in 2005. Madhav began his career in the pharmaceutical industry as a health economist in his mid-20's at Eli Lilly and Company based in Indianapolis. Over the next five years, Madhav held several roles in the company before leaving in 2003 to pursue an MBA in Marketing. He then spent two years at a medical devices company ConvaTec which at the time was part of Bristol-Myers Squibb. Madhav established a health economics research function at the medical devices company before leaving in 2005 to move to Bayer Schering Pharma. At Bayer, Madhav was the global market access lead for their Hemophilia product Kogenate and also worked closely with Regeneron on an Alliance for an ophthalmic product in age-related macular degeneration. In 2010, Madhav joined the U.S. Oncology Business Unit of Novartis in East Hanover, New Jersey where he developed health economic models to support their oncology agent for bone metastases Zometa. Madhav then moved to the commercial side of the business being on the Launch Management Team and later on the U.S. Brand Team for Afinitor in ER+HER2- Breast Cancer. After four years at Novartis, Madhav moved to Pfizer in New York City where he was part of the Global Launch Team for IBRANCE for patients with Breast Cancer. Since 2015, Madhav has focused on immuno-oncology and in 2017 was the launch lead for Pfizer's first immuno-oncology product BAVENCIO working closely on the Aliiance with Merck KGaA. Throughout his career, Madhav has been the recipient of multiple awards. Madhav intends to continue his pursuit to bring innovative medicines to the market to help both patients and physicians.

An expert in his field, Dr. Namjoshi has been recognized on many occasions for his professional accomplishments, earning a Career Development Award through the University of Toledo, and inclusion into prestigious publications such as Who's Who in America, Who's Who in American Education, Who's Who in Medicine and Healthcare, and Who's Who in Science and Engineering. In the near future, Dr. Namjoshi intends to continue his pursuit of knowledge in the field of medicine, so he can constantly advance the way in which he provides treatment for his patients.

About Marquis Who's Who :
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis publications may be visited at the official Marquis Who's Who website at

# # #

Contact Information:
Fred Marks
Marquis Who's Who Ventures LLC
Berkeley Heights, NJ
Voice: 844-394-6946

If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Use disclaimer for more information.
This News Release can be viewed online at: